Molecular Evolution of Hepatitis C Virus: From Epidemiology to Antiviral Therapy (Current Research in Latin America)

Response to: Comment on “Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients”

“…Nevertheless, we share the idea proposed by the authors [1] that having nationwide surveys would provide larger samples to support our studies. However, it is worth mentioning that such an approach would be very difficult to carry out in our country given that our HCV infection prevalence among general population is currently unknown [12]. In conclusion, following this line of thought, we believe that generalizations about the frequency of HCV resistance-associated substitutions (RASs) in the whole country are reasonably accurate.…”